Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IIb Study of RGX-314 to Treat Wet Age-Related Macular Degeneration (wet AMD)

Trial Profile

A Phase IIb Study of RGX-314 to Treat Wet Age-Related Macular Degeneration (wet AMD)

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 05 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs RGX 314 (Primary)
  • Indications Wet age-related macular degeneration
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Nov 2019 According to a REGENXBIO media release, the company anticipates a short delay in initiating this study, following notification from the FDA regarding certain third-party commercially-available surgical devices that were used to deliver RGX-314 in the Phase I/IIa trial. The company plans working with the FDA to address this matter, and as a result, the company plans to initiate this study in the first quarter of 2020.
    • 05 Nov 2019 According to a REGENXBIO media release, the study will commence in the first quarter of 2020.
    • 04 Sep 2019 According to a REGENXBIO media release, this trial is expected to begin by the end of 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top